This product has a broad-spectrum antibacterial effect and strong antibacterial activity, and has strong antibacterial activity against most Enterobacteriaceae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Mycoplasma pneumoniae, and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

Telmisartan is an oral specific non-peptide angiotensin II receptor (AT1 type) antagonist. It selectively binds to the AT1 receptor site with high affinity, persistently antagonizes angiotensin II, and causes a decrease in blood aldosterone levels, thereby reducing blood pressure. Telmisartan does not inhibit human plasma renin, nor does it block ion channels, nor does it inhibit angiotensin converting enzyme (kinase II), nor does it affect the enzyme's degradation of bradykinin, so there will be no adverse reactions caused by the enhanced effect of bradykinin. For patients with hypertension, telmisartan can reduce systolic and diastolic blood pressure without affecting heart rate. No rebound hypertension occurs after telmisartan is discontinued.

It has an antihistamine effect and can compete with histamine released from tissues for the H1 receptors on effector cells, thereby stopping allergic reactions; it inhibits central nervous system activity and causes sedative and hypnotic effects; it enhances the effects of antitussive drugs; it has anti-vertigo and anti-tremor paralysis effects; it has local anesthetic, antiemetic and anti-M cholinergic effects.

Oral acetanilide antipyretic analgesic may produce antipyretic and analgesic effects mainly by inhibiting the synthesis of prostaglandins

Long-acting tricyclic antihistamines that selectively antagonize peripheral H1 receptors to relieve nasal or non-nasal symptoms of seasonal allergic rhinitis

Adrenaline-mimetic drugs can constrict the blood vessels of the nasal mucosa and relieve symptoms of nasal congestion and runny nose

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.